Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3/4 in Healthy Volunteers
NCT04586673Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Oxford. Primary endpoint: Assessment of Safety. Started Jul 2021; status: completed.
02
Drugs
ChAdOx1.tHIVconsv1MVA.tHIVconsv3MVA.tHIVconsv4
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04586673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586673.